A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI-PD-1 THERAPY
Latest Information Update: 21 Apr 2025
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Pembrolizumab (Primary) ; Ipilimumab; Nivolumab
- Indications Malignant melanoma; Skin cancer
- Focus Therapeutic Use
- Acronyms PORTSIDE
- Sponsors Pfizer
Most Recent Events
- 16 Apr 2025 Planned End Date changed from 23 May 2027 to 25 Nov 2025.
- 16 Apr 2025 Planned primary completion date changed from 23 May 2025 to 25 Nov 2025.
- 09 Sep 2024 Status changed from recruiting to active, no longer recruiting.